ABVC ABVC BIOPHARMA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1173313 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY234.3%
TTM net income YoY62.5%
TTM EPS YoY76.7%
Revenue 3-yr CAGR12.7%
Net income 3-yr CAGR—
Margins
Gross margin99.9%
Operating margin-850.7%
Net margin-773.6%
FCF margin—
EBITDA margin-840.1%
Returns
ROE-283.6%
ROA-51.4%
ROIC (approx.)-570.9%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets90.4%
Debt / equity0.00x
Current ratio0.33x
Interest coverage-5.25x
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $296,000 | $509,589 |
| Cost of revenue | — | $763 |
| Gross profit | — | $508,826 |
| R&D expense | $121,085 | $179,272 |
| SG&A expense | $2.89M | $2.26M |
| Operating income | -$7.15M | -$4.71M |
| Interest expense | $415,890 | $825,899 |
| Pretax income | -$8.35M | -$5.37M |
| Income tax | $24,154 | -$110,539 |
| Net income | -$7.91M | -$4.90M |
| EBITDA | -$7.13M | -$4.67M |
| EPS (basic) | -0.39 | -0.42 |
| EPS (diluted) | -0.39 | -0.42 |
| Weighted avg. shares (diluted) | 20.11M | 11.67M |
| Balance sheet | ||
| Cash & equivalents | $681,480 | $863,815 |
| Short-term investments | $64,354 | $64,736 |
| Current assets | $3.26M | $2.18M |
| PP&E, net | $12.84M | $511,088 |
| Total assets | $21.82M | $7.54M |
| Current liabilities | $6.92M | $6.56M |
| Short-term debt | $755,512 | $840,252 |
| Total liabilities | $8.52M | $6.82M |
| Shareholders' equity | $11.11M | $1.23M |
| Shares outstanding | 25.05M | 13.87M |
| Cash flow statement | ||
| Operating cash flow | -$2.99M | -$1.81M |
| Investing cash flow | -$1.21M | — |
| Financing cash flow | $4.64M | $1.98M |
| Depreciation & amortization | $25,330 | $32,025 |
| Stock-based compensation | $4.14M | $2.77M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.